Adiponectin removal by the human kidney: A preliminary study.

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Nutrition Metabolism and Cardiovascular Diseases Pub Date : 2024-11-30 DOI:10.1016/j.numecd.2024.103812

Daniela Picciotto, Manrico Balbi, Gianmarco Rosa, Pasquale Esposito, Elisa Russo, Antonella Sofia, Valentina Zanetti, Francesca Cappadona, Michela Saio, Giacomo Garibotto, Francesca Viazzi, Daniela Verzola

{"title":"Adiponectin removal by the human kidney: A preliminary study.","authors":"Daniela Picciotto, Manrico Balbi, Gianmarco Rosa, Pasquale Esposito, Elisa Russo, Antonella Sofia, Valentina Zanetti, Francesca Cappadona, Michela Saio, Giacomo Garibotto, Francesca Viazzi, Daniela Verzola","doi":"10.1016/j.numecd.2024.103812","DOIUrl":null,"url":null,"abstract":"Background and aims: The adipocyte-derived adiponectin (APN) has potent insulin-sensitizing and anti-inflammatory properties. The adipose tissue is known to be the main source for APN in the circulation, but sites and mechanisms which remove APN from blood are still unknown in humans.Methods and results: We reviewed APN data obtained in previous studies in which the inter-organ exchange of amino acids and cytokines was measured in our laboratory. Results for kidney and splanchnic arterio-venous differences of APN were available for 5 subjects (age 57 ± 7 years, mean eGFR 79 ± 4 ml/min 1.73 m2). Both the liver and renal vein concentrations of total APN were lower than in the artery (by ∼32 and 20 %, respectively p < 0.05) indicating removal from blood; a similar trend (liver and renal vein level lower than the arterial by ∼22 and 15 %, respectively, p = NS) was observed for high molecular weight (HMW) APN.Conclusions: The present study identifies the splanchnic organs and the kidney as major sites for APN removal from blood in humans. Our data provide new understanding of kidney APN metabolism and suggests that reduced handling by the human kidney is a major factor to increase circulating APN in renal disease.","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":" ","pages":"103812"},"PeriodicalIF":3.3000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition Metabolism and Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.numecd.2024.103812","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: The adipocyte-derived adiponectin (APN) has potent insulin-sensitizing and anti-inflammatory properties. The adipose tissue is known to be the main source for APN in the circulation, but sites and mechanisms which remove APN from blood are still unknown in humans.

Methods and results: We reviewed APN data obtained in previous studies in which the inter-organ exchange of amino acids and cytokines was measured in our laboratory. Results for kidney and splanchnic arterio-venous differences of APN were available for 5 subjects (age 57 ± 7 years, mean eGFR 79 ± 4 ml/min 1.73 m²). Both the liver and renal vein concentrations of total APN were lower than in the artery (by ∼32 and 20 %, respectively p < 0.05) indicating removal from blood; a similar trend (liver and renal vein level lower than the arterial by ∼22 and 15 %, respectively, p = NS) was observed for high molecular weight (HMW) APN.

Conclusions: The present study identifies the splanchnic organs and the kidney as major sites for APN removal from blood in humans. Our data provide new understanding of kidney APN metabolism and suggests that reduced handling by the human kidney is a major factor to increase circulating APN in renal disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

人体肾脏去除脂联素的初步研究。

背景和目的：脂肪细胞源性脂联素（APN）具有有效的胰岛素增敏和抗炎特性。已知脂肪组织是循环中APN的主要来源，但在人类血液中清除APN的部位和机制仍然未知。方法和结果：我们回顾了在我们实验室测量的氨基酸和细胞因子的器官间交换的先前研究中获得的APN数据。5例受试者（年龄57±7岁，平均eGFR 79±4 ml/min 1.73 m2）肾脏和内脏动静脉APN差异。肝和肾静脉的总APN浓度都比动脉低（分别为32%和20%）。结论：本研究确定了内脏器官和肾脏是人类血液中APN去除的主要部位。我们的数据为肾脏APN代谢提供了新的认识，并表明人体肾脏处理的减少是肾脏疾病中循环APN增加的主要因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nutrition Metabolism and Cardiovascular Diseases 医学-内分泌学与代谢

CiteScore

6.80

自引率

2.60%

发文量

332

审稿时长

57 days

期刊介绍： Nutrition, Metabolism & Cardiovascular Diseases is a forum designed to focus on the powerful interplay between nutritional and metabolic alterations, and cardiovascular disorders. It aims to be a highly qualified tool to help refine strategies against the nutrition-related epidemics of metabolic and cardiovascular diseases. By presenting original clinical and experimental findings, it introduces readers and authors into a rapidly developing area of clinical and preventive medicine, including also vascular biology. Of particular concern are the origins, the mechanisms and the means to prevent and control diabetes, atherosclerosis, hypertension, and other nutrition-related diseases.